Hospital BICETRE
Le Kremlin-Bicêtre, 94275, France
NCT Number: NCT04744584
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex drug management. In France ,a part of these treatments ,only available in hospital pharmacies, are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects. Anticipating medication errors at the begging of the disease is therefore important, and could be done through medication reconciliation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Le Kremlin-Bicêtre, 94275, France
Medication reconciliation (MR) will be done for patients hospitalized in the French referral center for PH for PAH or CTEPH. Detected medication errors will be tracked and fixed by the physician before the end of hospitalization. A synthesis of new/stopped and modified treatments will be given to the patient as well as his related healthcare professionals (community pharmacist and general practioner) to ensure the maintaining of the new therapeutic management and the understanding of drugs modification. To compare the potential decrease of medication errors promoted by MR, a retrospective MR will be also done for patients without MR at 1st hospitalization but at the next one (3 to 12 months after).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
Time frame: 12months
This group will be compared to patients without prospective MR. For the latter group, MR is retrospective (3 to 6 months after discharge).
Time frame: 12 months
Omission, dosing errors, drug interactions, substitution of another active compound
Time frame: 12 Months
corrected/not corrected
Time frame: 12 months
Cornish scale is the title of the scale which include 3 levels of gravity (from 1 to 3). The first one describes no relevant clinical impact and the third one describes a severe clinical impact.
Time frame: 12 months
healthcare practitioners will be contacted by mail or phone
Time frame: within 12 months after first hospitalization for the diagnosis of the disease
Observance Girerd auto-questionnaire
Time frame: within 12 months after first hospitalization for the diagnosis of the disease
Short Form 36 Questionnaire
Time frame: within 12 months after first hospitalization for the diagnosis of the disease
inclusion vaccination coverage rate vs EOS(Enhanced Outreach Strategy) vaccination coverage rate
Time frame: within 12 months after first hospitalization for the diagnosis of the disease
Number of emergency hospitalizations between first assessment hospitalization (diagnosis) and first reassessment hospitalization
Time frame: 12 months
Time measurement of the conciliation process in the group with CM (in minutes)
Assistance Publique - Hôpitaux de Paris
Other
Optimizing Drug Management of Patients Suffering From Rare Disease Through Medication Reconciliation: Proof of Concept in Pulmonary Hypertension
Acronym: OPTICARE-HTP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02036970
Acute Interstitial Pneumonitis, Bronchial Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT06605326
Cardiovascular Diseases, Chronic Lung Disease-Associated Pulmonary Hypertension
View Trial DetailsNCT04663230
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension
Bad Nauheim, Hesse, Germany
View Trial Details